ImmunoScape

Executive Summary

ImmunoScape is a Singapore-based biotech spin-off from A*STAR developing a novel "seed-and-boost" immunotherapy platform for solid tumors. The platform combines tumor-specific TCR-T cells with an off-the-shelf booster molecule (CUE-102) designed to selectively expand and activate T cells in vivo, aiming to improve efficacy, safety, and cost-effectiveness over current cell therapies. Founded in 2016, the company has raised $150M and is currently in Phase 1 clinical development. Its differentiated approach addresses key limitations of adoptive cell therapies, such as poor persistence and tumor microenvironment suppression, by providing a controllable boost mechanism. The company's focus on TCR-T cells rather than CAR-T may offer advantages in targeting intracellular antigens common in solid tumors. ImmunoScape's platform has the potential to transform the treatment landscape for various solid tumor indications, though clinical validation remains early.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 initial efficacy and safety data readout for lead program60% success
• Q3 2026Potential partnership or licensing deal for CUE-102 booster molecule40% success
• Q4 2026IND filing for second indication or combination trial50% success